WCG Acquires Intrinsic Imaging
WCG has announced the acquisition of Intrinsic Imaging, a global provider of medical imaging core lab services. With over a decade of experience, a team of more than 500 board-certified physicians and comprehensive services in support of drug, medical device and artificial intelligence clinical trials, Intrinsic Imaging supports WCG’s scientific and regulatory capabilities, complementing the Company’s suite of solutions.
Moving forward, Intrinsic Imaging will be known as WCG Intrinsic Imaging. The organization will retain its leadership structure and continue to operate from its Bolton, Massachusetts headquarters.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
